Weekly Roundup: October 25-29

Step Up Skin Microbiome Understanding to Advance AD Treatment

People are born with sterile skin and then gain microbiota throughout their life. Lawrence J. Green, MD, FAAD, explains how this affects the skin barrier and ultimately plays a role in atopic dermatitis at the 2021 Fall Clinical Dermatology Conference.

Acne in Skin of Color: It’s All About PIH

Unlike Caucasian patients who are primarily concerned about the acne itself, skin of color patients prioritize postinflammatory hyperpigmentation.

Botulinum Type A: Key Clinical Postulates

Botulinum type A injections are widely used across the dermatology and aesthetic medicine specialties. At the Fall Clinical Dermatology Conference 2021, Mark S Nestor, MD, PhD, highlights how to optimize the neurotoxin to improve patient care.

First Topical JAK Inhibitor Treats Whole-body AD

FDA approval of ruxolitinib (Opzelura, Incyte) adds the first new topical anti-inflammatory to the atopic dermatitis (AD) armamentarium in 50 years, but boxed warnings raise questions.

What to Know: Phase 3 Findings on Promising Psoriasis Pipeline

Mark G. Lebwohl, MD, presents on what dermatologists need to know about the newest psoriasis studies during the Fall Clinical Dermatology Conference.

DermView Episode 2: How Ceramide Containing Creams Can Help AD

In this episode of DermView, Adelaide Hebert, MD, explains the clinical manifestations of eczema, how the chronic the condition is, and the benefits of using ceramide cream for management.

Dupilumab-Induced Psoriasiform Lesions Reported in Pediatric Patients

Investigators recommended a treatment course of at least 1-2 months with medium strength to potent topical corticosteroids should be considered before dupilumab discontinuation in affected children and adolescents.

Navigating the Savings Potential of Cash Balance Plans

In this month's OJM Group video series, Jason O'Dell, MS, CWM explains cash balance plans.

Tralokinumab Linked to Ocular Diseases in Patients with Atopic Dermatitis

Patients treated with the monoclonal antibody had increased incidences of conjunctivitis, though many of these incidences were considered mild and were resolved by the end of the study.

What to Look Forward to at NFCMMD

In this video, we talk to Michael Gold, MD, about the 11th annual New Frontiers in Cosmetic Medicine and Medical Dermatology symposium. He tells us the highlights of the conference and what makes it stands out from the rest.

What is causing physician burnout?

The assumption has been that the COVID-19 pandemic has been at the root of recent upticks in physician burnout.

Pointers With Dr Portela: How to Get Rid of Brown Spots

In this week’s Pointers with Dr Portela, the 208SkinDoc watches a TikTok and debunks its claim of what causes brown spots.

What’s Trending in Skin Care? October 2021

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of October.

NICE recommends antiseptics over antibiotics for impetigo

The National Institute for Health and Care Excellence and the Public Health England have issued guidance on impetigo.

Improve Outcomes for Impetigo

Literature update highlights the treatment methods, clinical pearls, and enhancement of outcomes for the disease.

Prenatal Exposure to Inorganic Arsenic, Cadmium Associated with Atopic Dermatitis Risk

Investigators suggested the prevention of exposure during pregnancy could help control atopic dermatitis and other potential allergies in pediatric populations.

FDA panel recommends Pfizer COVID-19 vaccine for children

A previous analysis found the vaccine was 90.7 percent effective against severe COVID-19.

Survey: Patients lean on digital resources when researching health care

Most respondents look online when finding a physician or other care entity.

Combination Therapy for Patients with Vitiligo Evaluated with the DLQI

Combined therapies such as ultraviolet light and tab methotrexate were deemed effective in the management of vitiligo.